{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:11:27Z","timestamp":1767967887684,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:00:00Z","timestamp":1477612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A previously published population PK model for daptomycin was updated with data from patients undergoing continuous veno\u2010venous haemodialysis (CVVHD; <jats:italic>n<\/jats:italic>\u00a0=\u00a09) and continuous veno\u2010venous haemodiafiltration (CVVHDF; <jats:italic>n<\/jats:italic>\u00a0=\u00a08). Model\u2010based simulations were performed to compare the 24\u00a0h AUC, <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>C<\/jats:italic><jats:sub>min<\/jats:sub> of daptomycin following various dosing regimens (4, 6, 8, 10, and 12\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup> every [Q] 24\u00a0h and Q48\u00a0h), with the safety and efficacy exposure references for <jats:italic>Staphylococcus aureus<\/jats:italic> bacteraemia\/right\u2010sided infective endocarditis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The previously developed daptomycin structural population PK model could reasonably describe data from the patients on CRRT. The clearance in patients undergoing CVVHDF and CVVHD was estimated at 0.53 and 0.94\u00a0l\u00a0h<jats:sup>\u22121<\/jats:sup>, respectively, as compared with 0.75\u00a0l\u00a0h<jats:sup>\u22121<\/jats:sup> in patients with creatinine clearance (CrCl) \u2265 30\u00a0ml\u00a0min<jats:sup>\u22121<\/jats:sup>. Daptomycin Q24\u00a0h dosing in patients undergoing CRRT resulted in optimal exposure for efficacy, with AUC comparable to that in patients with CrCl \u2265 30\u00a0ml\u00a0min<jats:sup>\u22121<\/jats:sup>. In contrast, Q48\u00a0h dosing was associated with considerably lower AUC<jats:sub>24\u201348h<\/jats:sub> in all patients for doses up to 12\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup> and is therefore inappropriate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Q24\u00a0h dosing of daptomycin up to 12\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup> provides comparable drug exposure in patients on CVVHD and in those with CrCl \u2265 30\u00a0ml\u00a0min<jats:sup>\u22121<\/jats:sup>. Daily daptomycin use up to 8\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup> doses are appropriate for patients on CVVHDF, but higher doses may increase the risk of toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13131","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T07:22:48Z","timestamp":1473924168000},"page":"498-509","source":"Crossref","is-referenced-by-count":26,"title":["Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy"],"prefix":"10.1111","volume":"83","author":[{"given":"Xiaoying","family":"Xu","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Khadzhynov","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Campus Mitte Charit\u00e9 \u2013 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Campus Mitte Charit\u00e9 \u2013 Universit\u00e4tsmedizin  Berlin Germany"},{"name":"Dieter Scheffner Center for Medical Education and Educational Research Charit\u00e9 \u2013 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo L.","family":"Chaves","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"Levi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natascia","family":"Corti","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology Zurich University Hospital  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.427"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.7.813"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.1.2.141.62908"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja A","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"e_1_2_9_6_1","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int"},{"key":"e_1_2_9_7_1","first-page":"197","article-title":"Invasive methicillin\u2010resistant Staphylococcus aureus infections among dialysis patients \u2013 United States, 2005","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2006.02.011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1681\/ASN.V471413","article-title":"A comparison of metabolic control by continuous and intermittent therapies in acute renal failure","volume":"4","author":"Clark WR","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2003.07283.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.152"},{"key":"e_1_2_9_14_1","unstructured":"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc.Cubicin (Daptomycin) Prescribing Information 2015[online]. Available athttps:\/\/www.merck.com\/product\/usa\/pi_circulars\/c\/cubicin\/cubicin_pi.pdf(last accessed 1 October 2016)."},{"key":"e_1_2_9_15_1","unstructured":"Novartis Pharmaceuticals UK Ltd.Cubicin powder for concentrate for solution for injection or infusion. Summary of Product Characteristics 2015. Available athttp:\/\/www.medicines.org.uk\/emc\/medicine\/17341(last accessed 1 October 2016)."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt342"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353400"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201626"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2799-2807.2004"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12052"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/652767"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000097078"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2003.07288.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181fa36fb"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.318"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.10.030"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01291-10"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2015.03.014"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2008.09.003"},{"key":"e_1_2_9_32_1","first-page":"234","article-title":"Guidelines for the treatment on infections caused by methicillin\u2010resistant Staphylococcus aureus","volume":"21","author":"Mensa J","year":"2008","journal-title":"Rev Esp Quimioter"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-012-0300-3"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31820f6d58"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr551"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000033"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01224-10"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2005.05008.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13131","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13131","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:53:39Z","timestamp":1696254819000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,28]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bcp.13131"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13131","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,28]]}}}